JP2024522164A5 - - Google Patents
Info
- Publication number
- JP2024522164A5 JP2024522164A5 JP2023575496A JP2023575496A JP2024522164A5 JP 2024522164 A5 JP2024522164 A5 JP 2024522164A5 JP 2023575496 A JP2023575496 A JP 2023575496A JP 2023575496 A JP2023575496 A JP 2023575496A JP 2024522164 A5 JP2024522164 A5 JP 2024522164A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- peptide
- glutamine
- domain peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208407P | 2021-06-08 | 2021-06-08 | |
| US63/208,407 | 2021-06-08 | ||
| PCT/US2022/032539 WO2022261121A1 (en) | 2021-06-08 | 2022-06-07 | Antibody-nkg2d ligand domain fusion protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522164A JP2024522164A (ja) | 2024-06-11 |
| JP2024522164A5 true JP2024522164A5 (enExample) | 2026-03-13 |
Family
ID=82403490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575496A Pending JP2024522164A (ja) | 2021-06-08 | 2022-06-07 | 抗体－ｎｋｇ２ｄリガンドドメイン融合タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240277845A1 (enExample) |
| EP (1) | EP4351635A1 (enExample) |
| JP (1) | JP2024522164A (enExample) |
| KR (1) | KR20240018434A (enExample) |
| CN (1) | CN117412768A (enExample) |
| AU (1) | AU2022291369A1 (enExample) |
| BR (1) | BR112023025884A2 (enExample) |
| CA (1) | CA3220872A1 (enExample) |
| IL (1) | IL307945A (enExample) |
| MX (1) | MX2023014118A (enExample) |
| PH (1) | PH12023553282A1 (enExample) |
| WO (1) | WO2022261121A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240018435A (ko) * | 2021-06-08 | 2024-02-13 | 사이포스 바이오사이언시스 인코포레이티드 | 항체-nkg2d 리간드 도메인 융합 단백질 |
| TW202448960A (zh) | 2023-02-07 | 2024-12-16 | 美商Ｇｏ治療公司 | 包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途 |
| EP4661901A1 (en) | 2023-02-07 | 2025-12-17 | Xyphos Biosciences Inc. | Chimeric antigen receptor and antibody-nkg2d ligand domain fusion protein |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE69831754T2 (de) * | 1997-12-17 | 2006-06-29 | Immunex Corp., Thousand Oaks | Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden |
| KR102844238B1 (ko) * | 2018-03-27 | 2025-08-07 | 사이포스 바이오사이언시스 인코포레이티드 | 비천연 nkg2d 수용체를 결합하는 비천연 nkg2d 리간드의 변형된 a1-a2 도메인 |
| MX2021009020A (es) * | 2019-01-28 | 2021-09-28 | Xyphos Biosciences Inc | Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car. |
-
2022
- 2022-06-07 US US18/568,405 patent/US20240277845A1/en active Pending
- 2022-06-07 IL IL307945A patent/IL307945A/en unknown
- 2022-06-07 WO PCT/US2022/032539 patent/WO2022261121A1/en not_active Ceased
- 2022-06-07 CA CA3220872A patent/CA3220872A1/en active Pending
- 2022-06-07 MX MX2023014118A patent/MX2023014118A/es unknown
- 2022-06-07 CN CN202280039631.7A patent/CN117412768A/zh active Pending
- 2022-06-07 EP EP22738129.0A patent/EP4351635A1/en active Pending
- 2022-06-07 BR BR112023025884A patent/BR112023025884A2/pt not_active Application Discontinuation
- 2022-06-07 PH PH1/2023/553282A patent/PH12023553282A1/en unknown
- 2022-06-07 KR KR1020237039553A patent/KR20240018434A/ko active Pending
- 2022-06-07 AU AU2022291369A patent/AU2022291369A1/en active Pending
- 2022-06-07 JP JP2023575496A patent/JP2024522164A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540732A5 (enExample) | ||
| RU2505603C2 (ru) | Антитело против рецептора il-6 | |
| NZ596865A (en) | Single-chain multivalent binding proteins with effector function | |
| JP2020515508A5 (enExample) | ||
| JP2018515084A5 (enExample) | ||
| JP2014510518A5 (enExample) | ||
| CN109641046A (zh) | 单链可变片段cd3结合蛋白质 | |
| JP2011511780A5 (enExample) | ||
| WO2002044217A3 (en) | Humanised antibodies and uses thereof | |
| PL363071A1 (pl) | Sposoby i kompozycje dla zmniejszenia replikacji HIV-1 | |
| JP2018519802A5 (enExample) | ||
| CN119032104A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2026004299A5 (enExample) | ||
| JP2022542670A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| JP2023116739A5 (enExample) | ||
| MX2023014118A (es) | Proteina de fusion de anticuerpo con dominio del ligando de nkg2d. | |
| RU2004106618A (ru) | Изолированные полипептиды на основе нейтрализующего эпитопа белка р17 вируса вич, используемые в качестве вакцин, а также нейтрализующие анти-р17-антитела, специфически распознающие указанный нейтрализующий эпитоп | |
| RU2015126663A (ru) | Гуманизированное антитело против hmgb1 или антиген-связывающий фрагмент указанного антитела | |
| MXPA06014393A (es) | Peptidos oligomericos y su uso para el tratamiento de infecciones por vih. | |
| RU2007119376A (ru) | Тимус - специфический белок | |
| JP2019518713A5 (enExample) | ||
| JP2025512749A5 (enExample) | ||
| JP7174429B2 (ja) | コラーゲンへの結合活性を有する環状ペプチド | |
| JP2024501767A5 (enExample) |